 |
Walden Biosciences
Last updated: August 28, 2024
Blaine McKee, CEO
USA | Funding: $51M (+)
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
Walden Biosciences develops drugs for kidney disease, taking a two-pronged approach: antibodies and small molecules.
